Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.

Eylea has been one of Regeneron's top growth ... Regeneron and Sanofi are also seeking a label expansion for Dupixent in treating a rare skin disease called bullous pemphigoid.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

But the private label has been maturity of our business so ... our proposed biosimilars to Prolia Xtiva, to Symphony and to EYLEA. So those are moving nicely and we’re looking forward to them ...

So we think we’re going to be in a good position to really support a broad label of one and over ... the other is against the active comparator Eylea loading doses plus the standard every ...

The system recorded a spike in intraocular inflammation of Eylea in February 2018 but these ... a contraindication on the drug’s label, and Welford added that a similar proportion of patients ...

It has also instructed clinicians to use the least expensive option among the available treatments for wet AMD, which include Bayer's Eylea (aflibercept ... only be used off-label for ophthalmic ...